According to the ICER, Wegovy should be priced at $7,500$9,800 per year to fall into the cost-effective threshold
Given the costs associated with these treatments and the observed results, it is recommended to stop DPP-4 inhibitors in patients who do not achieve glycemic targets before introducing a GLP-1 RA, in accordance with current ADA guidelines
Remember that every body responds differently, and what works for one person may require adjustment for another
They are actively involved in research to develop new formulations and enhance therapeutic efficacy
Also in that trial, T2D and obesity were not inclusion criteria and the median BMI at baseline was 28 kg/m 2 in the liraglutide group and 29.8 kg/m 2 in the placebo group
By most measures, the new GLP-1 pills are underwhelming